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Background: Gastric cancer relapse occurs in about 30% of the patients treated with gastrectomy and D2-
lymphadenectomy, mainly as distant or peritoneal metastases. Hyperthermic intraperitoneal chemotherapy (HIPEC)
has been associated with an improvement in survival and lower peritoneal recurrence, albeit with increased
morbidity. The aim of this study is to report the preliminary results of the association of perioperative
chemotherapy, radical surgery and HIPEC in high-risk gastric patients in a single institution.
Methods: Treatment protocol was started in 2007 and included patients younger than 65 years old, with good
performance status and gastric adenocarcinoma with serosa involvement and lymph node metastases, located in
the body or antrum. Patients should receive three preoperative cycles of DCF (Docetaxel 75 mg/m2, Cisplatin
75 mg/m2 and continuous intravenous infusion of 5-Fluorouracil 750 mg/m2 for 5 days), followed by gastric
resection with D2-lymphadenectomy, hyperthermic intraperitoneal chemotherapy with Mytomicin C 34 mg/m2 and
three more postoperative cycles of DCF.
Results: Ten patients were included between 2007 and 2011. Their median age was 47 years old and six were
male. Nine were staged with cT4 cN+ tumors and one as cT3 cN+. Nine patients completed all three preoperative
chemotherapy cycles. Eight individuals were treated with a total gastrectomy and the other two had a distal
gastrectomy, all having HIPEC. Postoperative morbidity was 50%, with no deaths. Regarding postoperative
chemotherapy, only 5 patients completed three cycles. With a median follow-up of 25 months, three relapses were
identified and 7 patients remain disease-free, two with more than 4 years of follow-up.
Conclusion: The association of perioperative systemic and intraperitoneal chemotherapy plus radical surgery is a
feasible multimodality treatment, with acceptable morbidity. With a longer follow-up and a larger group of patients,
we hope to be able to determine if it also influences survival outcomes and patterns of recurrence.
Mini-Abstract: The association of perioperative chemotherapy, gastric resection and D2-lymphadenectomy and
hyperthermic intraperitoneal chemotherapy proved to be associated with acceptable morbidity. For survival
analysis, a longer follow-up is needed.
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The surgical treatment of gastric cancer in western
countries has been associated with 5-year survival rates
of between 20 and 30% [1]. This number is quite small
compared with that observed in Eastern historical
series, of around 60% [2], and in recent randomized
studies of stage II and III patients who had 3-year sur-
vival of over 70% [3]. This difference has been attribu-
ted to a higher incidence of proximal tumors and
more advanced disease at diagnosis [1]. However, the
extent of surgery seems to have a major role in it. In
Japan, for patients with tumors in stages IB through
IIIC, according to the seventh edition of the so-called
tumor, node, metastasis (TNM) staging system [4], the
guidelines for surgical treatment recommend resection
with D2-lymphadenectomy [5]. On comparison of
Japanese survival rates with those in Western cancer
centers where extended lymphadenectomy has been
routinely performed, the numbers are very similar [6].
Even with optimal surgery, more than 30% of patients
will have tumor relapse in the first two years of follow-
up, primarily as peritoneal or distant visceral metastasis
[7,8]. These results favor a multimodal approach in the
treatment of gastric cancer. The first relevant Western
trial was the INT 0116, which demonstrated an im-
provement in overall and disease-free survival with adju-
vant chemoradiation after a negative-margin resection
[9]. Surgical quality control was a weak point in this
trial, in which only 10% of patients underwent a D2 dis-
section. Interestingly, this group of individuals had no
survival benefit with adjuvant treatment [9]. In 2006, the
Medical Research Council adjuvant gastric infusional
chemotherapy (MAGIC) trial showed that patients who
had perioperative chemotherapy and surgery had better
overall and disease-free survival [10]. Some of the bene-
fits of neo-adjuvant treatment were revealed in this
study, as it allows early treatment of micrometastases
and increases the probability of an R0 resection [11].
Another modality in the multidisciplinary treatment of
gastric cancer is intraperitoneal chemotherapy. It has
been shown to improve survival in patients treated with
D2-lymphadenectomy and to reduce peritoneal recur-
rence [12]. A recent meta-analysis associated hyperther-
mic intraperitoneal chemotherapy, with or without early
postoperative intraperitoneal chemotherapy, and super-
ior overall survival numbers, albeit with increased mor-
bidity [13].
The aim of this study is to report the initial experience
of a single Brazilian Cancer Center with a protocol of
multimodal treatment in selected patients with locally
advanced gastric cancer. It includes the association of
perioperative chemotherapy, gastrectomy with D2-
lymphadenectomy and hyperthermic intraperitoneal
chemotherapy (HIPEC).Methods
Patients
Only patients under 65 years of age with Karnofsky per-
formance status (KPS) over 70% were included in this
protocol. Laboratory results included normal Hb/Ht and
leucogram and preserved renal (creatinine ≤ 1.5 mg/dl,
BUN ≤ 30 mg/dl) and hepatic (bilirubin < 2 mg/dl) func-
tions. They also had to have microscopically confirmed
diffuse-type adenocarcinoma, located in the body or an-
trum of the stomach and have been clinically staged as
non-metastatic T3 N+or T4 tumors, according to the
TNM staging proposed by the American Joint Commit-
tee on Cancer [4].
Exclusion criteria included prior history of any neo-
plasm; impairment from clinical conditions; tumors of
the gastric stump; gastroesophageal junction tumors;
T1-2-3 N0 or T1-2 N1 lesions, and M1 disease at
diagnosis.
Pretreatment staging included upper endoscopy with
biopsy, chest and abdominal multi-slice computer tom-
ography (CT), laparoscopy and endoscopic ultrasound
with fine needle aspiration, if necessary. The laparo-
scopic procedure should have included the placement of
a 10-mm infra-umbilical port and one or two additional
5 to 12 mm ports, as necessary. A thorough examination
of peritoneal and liver surfaces should have been per-
formed followed by peritoneal washing for cytology ana-
lysis. Enlarged regional lymph nodes were reported, but
not biopsied.
Beginning in 2007, ten patients were included in this
protocol. All of them were staged with upper gastro-
intestinal endoscopy, thoracic and abdominal CT. A
laparoscopy was performed in nine patients; one patient
refused to have the laparoscopic procedure prior to
neoadjuvant therapy. Eight patients had endoscopic
ultrasound examination. Nine patients were staged as
cT4 cN+ and one as cT3 cN+ .
Written informed consent was obtained for all
patients included in this study. The Ethics Committee
at A. C. Camargo Hospital, São Paulo, Brazil, approved
the protocol.Treatment
Patients who fit all eligibility criteria were seen by a group
of oncologists and started on preoperative chemotherapy
comprising docetaxel, cisplatin and 5-fluorouracil (DCF)
as follows: docetaxel 75 mg/m2, cisplatin 75 mg/m2
and continuous intravenous infusion of 5-fluorouracil
750 mg/m2 for 5 days. The treatment plan included
three preoperative cycles of chemotherapy followed by
surgery and three postoperative cycles of chemotherapy.
Treatment-related hematological toxicity was evaluated
according to CTCAE v4.0.
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upper endoscopy, thoracic and abdominal CT and endo-
scopic ultrasound, when available. Partial response was
defined as decreased gastric wall thickening, lymph node
size or number on CT, or lesion measure of more than
20% on upper endoscopy, or as significant relief from
clinical symptoms. Gastric wall involvement, and num-
ber and size of perigastric lymph nodes were also ana-
lyzed by endoscopic ultrasound.
Surgical treatment consisted of total or distal gastrec-
tomy and D2-lymphadenectomy. Frozen sections of the
negative margins were obtained. Extended resections,
such as splenectomy or pancreatectomy, were performed
only when deemed necessary so that negative margins
could be achieved.
After resection and reconstruction, just prior to tem-
porary abdominal closure, a perfusion system was pre-
pared and HIPEC was administered. Our HIPEC
system is a closed circuit, allowing perfusate circulation
with a variable dynamic flow of 500 to 3000 mL/mi-
nute and hyperthermic capability ranging between 38
to 45°C. A five-branched inflow catheter was inserted
in the abdomen toward the subdiaphragmatic surfaces,
the pericolic spaces and the pelvic recess. Conversely, a
three-branched outflow catheter was directed to the
diaphragmatic surfaces within the pouch of Douglas.
Approximately 3 to 4 L of dialysis solution containing
34 mg/m2 mitomycin C was circulated for 90 minutes.
Mitomycin C was used as it had been shown to have
an acceptable toxicity profile on intraperitoneal use for
gastric cancer [12] and it would be associated with sys-
temic chemotherapy, which at first could increase post-
operative morbidity and mortality. Temperature control
was established with simultaneous positioning of three
intra-abdominal thermometers, following the distribu-
tion of inflow and outflow catheters. Intra-abdominal
temperature should reach numbers between 40 and
42°C in all three thermometers. Close attention was
performed to the cardiac and respiratory function and
an intra-esophageal thermometer was inserted to con-
trol body temperature.
Postoperative morbidity was described using the modi-
fied Clavien classification for surgical complications [14].
Pathological analysis
All the resection specimens were evaluated according to
a standardized protocol. They were opened and the
macroscopically identifiable tumor or area of the stom-
ach with scarring indicating the site of the previous
tumor (tumor bed) was cross-sectioned serially at
0.5 cm intervals. These tissue sections were stained with
hematoxylin and eosin and period acid-Schiff (PAS) stain
was performed in some cases. Surgical resection mar-
gins, portions of the corpus and antrum, and lymphnodes were evaluated separately. The extent of the
tumor (TNM classification) and the completeness of re-
section (R) were determined according tp the guidelines
of the International Union Against Cancer (UICC).
Follow-up
Every patient included in this study started follow-up
after the last cycle of postoperative chemotherapy or for
those who did not receive adjuvant therapy, after the
surgical procedure. Appointments were scheduled every
three months for the first two years, at a six-month
interval for the next three, and yearly thereafter. Patients
had to have had a physical examination, a complete
blood count, liver-function testing, and abdominal and
thoracic CT.
Statistical analysis
A preliminary survival analysis was performed. Overall
survival was determined and its interval was established
by the time in months between surgery and death or the
last hospital visit. The overall survival curves were
obtained through the Kaplan-Meier method.
Results
Patients
Between April 2007 and December 2011, 10 patients
were included and treated according to our protocol. Six
of them were male and four female. Mean age was
47.6 years, range 34 to 63 years. In the beginning of
treatment, the KPS was over 80% for all patients. One
person had high blood pressure. Familial history was an
interesting element in this cohort of patients, as there
was one prior case of esophageal squamous cell carcin-
oma, one of laryngeal cancer, two of non-Hodgkins’
lymphoma and one of breast ductal carcinoma.
Staging and treatment
Regarding neoadjuvant treatment, nine patients com-
pleted three cycles as proposed. One patient had his
chemotherapy interrupted after two cycles, due to
gastrointestinal toxicity. Table 1 describes the toxicity
associated with the proposed treatment.
Evaluation work-up after neoadjuvant chemotherapy
included upper gastrointestinal endoscopy, and thoracic
and abdominal CT for all patients, and endoscopic ultra-
sound for four of them. In seven patients a partial clin-
ical response was observed and there were three other
patients with stable disease. No disease progression was
described.
Surgical treatment consisted of a total gastrectomy in
eight patients and a distal resection in two. In all
patients, D2-lymphadenectomy was performed with a
median of 33 dissected nodes. An R0 resection was
achieved in every case, and in three patients a distal
Table 1 Toxicity profile of patients treated with perioperative and hyperthermic intraperitoneal chemotherapy
Event Grade 3/4
Preoperative chemotherapy Postoperative chemotherapy
1 2 3 1 2 3
Adverse events, n/total 5/10 3/10 1/10 2/10 2/10 6/10
Grade 3/4 events 4/10 3/10 1/10 2/10 0/10 2/10
Non-hematological toxicity 3 3 1 2 0 1
Fatigue 0 0 0 0 0 0
Anorexia 0 1 0 0 0 0
Gastrointestinal 1 2 1 2 0 1
Mucositis 2 0 0 0 0 0
Rash 0 0 0 0 0 0
Alopecia 0 0 0 0 0 0
Fever 0 0 0 0 0 0
Hematological toxicity 1 0 0 0 0 1
Pancytopenia 0 0 0 0 0 0
Neutropenia 1 0 0 0 0 1
Total events 4 3 1 2 0 2
Results are presented as number of patients. Hematological toxicity was evaluated according to CTCAE v4.0. All grade 3/4 adverse events are described in Table 1.
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dian operative time was 450 minutes, and intraoperative
blood transfusion was needed in only patient.
The overall postoperative morbidity rate was 50%. By
stratifying complications as proposed by Dindo et al.
[14], we identified three grade II, one grade IIIa and one
grade IIIb events. Three patients had fever between the
7th and 9th postoperative days, with no identification of
an infection site, were treated with empiric antibiotics,
and discharged between the 10th and 13th day, without
any new event. One patient was diagnosed with a pan-
creatic fistulae through the identification of an abnormal
discharge in the closed suction drain placed during sur-
gery, and confirmed by a fluid amylase examination. No
additional treatment was necessary. Another patient, the
second in our series, had an intra-abdominal abscess
that required re-laparotomy. There was no postoperative
mortality.
The treatment protocol established that all patients
received three more cycles of DCF. However, the toxicity
profile in the postoperative setting was much more se-
vere. Only five patients completed three more cycles as
proposed. One patient refused adjuvant chemotherapy,
two had their treatment interrupted after the first cycle
due to gastrointestinal toxicity, and the other two
patients received only cisplatin and 5-fluorouracil during
the second and third cycle.
Treatment response and preliminary survival results
Pathological analysis demonstrated one pathologic
complete response and three patients with ypT1-2tumors, but in the others over 50% of viable tumor
(minor response) was identified in the surgical specimen.
Median follow-up was 25 months, ranging from 9 to
60 months. One patient had tumor relapse after
4 months of treatment, with distant lymph node and
brain metastasis, and died two months later. Two
patients developed peritoneal relapse, one 90 days after
surgery, and the other after 15 months of follow-up.
Seven patients are alive and without disease at the time
of writing this report (Table 2).
Discussion
Our study demonstrated the preliminary results of a
multimodality treatment protocol that involved the as-
sociation of perioperative systemic and intraoperative
hyperthermic chemotherapy with radical surgical treat-
ment. Optimal surgery for gastric cancer includes a
gastric resection with adequate margins [15] and D2-
lymphadenectomy, which has been associated with
higher survival rates in the East [16], and also in some
Western countries [17]. This is the standard for cura-
tive surgery at our institution, also with the emphasis
on obtaining a lower ratio between the metastatic and
dissected lymph nodes (N-ratio), as demonstrated in a
previous paper [18]. Even with adequate surgical treat-
ment, gastric cancer still recurs in more than 30% of
patients [7,8]. However, patterns of disease recurrence
tend to differ with the extent of lymphadenectomy. In
a large retrospective series with 2328 patients treated
with D2 dissection, overall recurrence was 28%. Peri-
toneal relapse was the most common (43.9%), followed












1 56 F T4 N+ SD Postoperative
fever
T2 N0 M0 28 Alive, without
disease
2 62 M T4 N+ PR Intraabdominal
abscess
T4a N2 M0 60 Alive, without
disease
3 34 F T4 N+ PR T2 N0 M0 10 Death due to
cancer
4 47 M T4 N+ SD Pancreatic
leakage
T4a N3a M0 26 Death due to
cancer
5 49 F T4 N+ PR T4a N3a M0 33 Alive, without
disease
6 50 M T4 N+ PR Postoperative
fever
T1N1M0 52 Alive, without
disease
7 39 M T4 N+ SD T4a N3b M0 9 Death due to
cancer
8 49 M T4 N+ PR T0 N0 M0 22 Alive, without
disease
9 56 M T4 N+ PR Postoperative
fever
T4aN3aM0 20 Alive, without
disease
10 34 F T3 N+ PR T3N3aM0 24 Alive, without
disease
F, female; M, male.
Pathology staging: T, tumor; N, node; M, metastasis.
Costa et al. World Journal of Surgical Oncology 2012, 10:195 Page 5 of 7
http://www.wjso.com/content/10/1/195by haematogenous and loco-regional events, which hap-
pened in 34.3% and 32.5% of the patients [7]. In one
large Western series, among 1172 patients treated with
an R0 resection for gastric cancer, there was a 42.3%
recurrence. Loco-regional recurrence was the most
common, in 54% of the cases, followed by distant
(51%) and peritoneal (29%) relapse. However, this series
included a high number of patients with esophagogas-
tric junction tumors (44.4%) and 19% of the individuals
had a D1-lymphadenectomy [8]. In other studies, when
a D2-lymphadenectomy was performed in all patients,
peritoneal and distant recurrences were more common;
nonetheless, when D1-dissections were included, loco-
regional relapses tended to increase [7,8,19].
Neoadjuvant and adjuvant therapies are associated
with different patterns of disease relapse. The addition
of postoperative chemoradiation in the INT0116 trial
was related to superior overall and disease-free survival
and a significant decrease in local recurrence, but not in
peritoneal or distant metastasis. Moreover, adjuvant che-
moradiation somehow managed to compensate a poor
surgical treatment, since a D2-lymphadenectomy was
performed in only 10% of the patients [9]. In the
MAGIC trial, the group treated with perioperative
chemotherapy and surgery had lower incidence of loco-
regional recurrence and distant metastasis. Statistical
analysis of this data was not performed [10]. This same
study demonstrated some of the advantages ofneoadjuvant treatment, as more than 90% of the patients
completed all three preoperative cycles of chemotherapy,
but only 42% completed all six cycles. This can be
explained by the nutritional impairment that gastrec-
tomy patients tend to suffer after surgery, which may
delay or even cancel any adjuvant treatment. Moreover,
in a recent European trial, individuals who were treated
with preoperative chemotherapy had tumor downstaging
and a higher number of R0 resections and N0 tumors
[20]. At last, the Eastern trial of adjuvant chemotherapy
with S-1 demonstrated an improvement in 3-year overall
and disease-free survival, and it was also the first study
in which a systemic treatment was associated with a de-
crease in peritoneal recurrence [3].
HIPEC, along with surgical cytoreduction, is part of
the standard treatment for peritoneal mesothelioma and
pseudomyxoma peritonei, and also a very important tool
in the treatment of peritoneal carcinomatosis of colorec-
tal and ovarian cancer [21]. Recently, surgical cytoreduc-
tion and HIPEC for the treatment of peritoneal
carcinomatosis of gastric cancer was associated with a
20% 5-year survival in selected patients [22].
When patients are treated with a D2-lymphadenect-
omy, loco-regional recurrences are less common, and
peritoneal relapse may occur in up to 40% of the indivi-
duals [7]. That is the rationale for the use of intraperito-
neal chemotherapy as a tool in the multimodal treatment
of patients with M0 gastric cancer.
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early postoperative intraperitoneal chemotherapy with
mitomycin C and 5-fluorouracil in stage II and III
patients after curative surgery. There was no survival
benefit in the whole set of patients. However, in the sub-
group of individuals with stage III disease, there was a
significant improvement in overall survival (49.1% vs.
18.4%). Decreasing incidence of peritoneal dissemination
after surgery with early postoperative intraperitoneal
chemotherapy was also observed [23]. Another Eastern
randomized trial investigated the use of HIPEC as part
of the surgical procedure. It included 141 patients and
identified a significant improvement in overall survival
in the multimodality group after 2, 4 and 8 years (88%
vs. 77%; 76% vs. 58%; 62% vs. 49%, respectively). Death
due to peritoneal recurrence was significantly reduced
(one patient in the multimodality group and sixteen in
the surgery-only group) [12]. In an attempt to assess the
effectiveness and safety of adjuvant intraperitoneal
chemotherapy in the treatment of gastric cancer, a meta-
analysis of 13 studies was published in 2007. There was
an improvement in overall survival with the addition of
HIPEC, followed or not by early postoperative intraperi-
toneal chemotherapy. There were also higher risks of
intra-abdominal abscess and neutropenia [13].
As the results of surgical and multimodality studies
have demonstrated, we believe that the set of combined
treatment to be instituted in a population should focus
on loco-regional recurrence when sub-optimal surgery is
performed, or on peritoneal and distant relapse, when
patients are routinely treated with D2-lymphadenect-
omy, as is the case in our service.
Morbidity could be increased with the addition of
HIPEC, which prompted us to focus on the toxicity
associated with it. As expected, over 90% of the patients
completed the first three cycles of chemotherapy, with
only one individual having grade 3 toxicity events. The
postoperative morbidity was high (50%), but only two
patients had grade III complications, with one of them
demanding exploratory surgery. The association of
neoadjuvant and intraperitoneal chemotherapy has
already been investigated in a Western phase II study, in
which preoperative cisplatin and 5-fluorouracil was fol-
lowed by gastrectomy with D2-lymphadenectomy and
early postoperative intraperitoneal chemotherapy. There
were 38 patients in the study, and around 80% of them
had T3 and node-positive disease. The treatment was
not associated with an increase in morbidity, but was
associated with higher R0 resection rates and a 39% 5-
year survival [24]. Recently, an Eastern study investi-
gated the use of neoadjuvant S-1 followed by surgery
and intraperitoneal paclitaxel in 12 patients with positive
peritoneal cytology, with no postoperative deaths. In
75% of them, no peritoneal metastases were foundduring surgery and their peritoneal washing was negative
[25].
Our results should be interpreted with caution, as the
small number of patients and a relatively short time of
follow-up may limit any conclusion regarding survival.
However, we believe that this study demonstrates that
the association of perioperative systemic and intraperito-
neal hyperthermic chemotherapy plus radical surgery is
a feasible multimodality treatment, with acceptable mor-
bidity. With a longer follow-up and a larger group of
patients, we hope to be able to determine if it also influ-
ences survival outcomes and patterns of recurrence.
Conclusion
The association between perioperative chemotherapy,
radical surgery and intraperitoneal hyperthermic chemo-
therapy is a safe and feasible multimodality treatment.
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